BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 24837348)

  • 1. B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias.
    Levine YC; Rosenberg MA; Mittleman M; Samuel M; Methachittiphan N; Link M; Josephson ME; Buxton AE
    Heart Rhythm; 2014 Jul; 11(7):1109-16. PubMed ID: 24837348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-terminal pro-B-type natriuretic peptide is a specific predictor of appropriate device therapies in patients with primary prevention implantable cardioverter-defibrillators.
    Sroubek J; Matos J; Locke A; Kaplinskiy V; Levine YC; Shen C; Buxton AE
    Heart Rhythm; 2021 Jan; 18(1):71-78. PubMed ID: 32866691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of N-terminal pro-brain natriuretic peptide versus electrophysiologic study for predicting future outcomes in patients with an implantable cardioverter defibrillator after myocardial infarction.
    Yu H; Oswald H; Gardiwal A; Lissel C; Klein G
    Am J Cardiol; 2007 Aug; 100(4):635-9. PubMed ID: 17697820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amino-terminal pro-brain natriuretic peptide predicts ventricular arrhythmogenesis in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillators.
    Manios EG; Kallergis EM; Kanoupakis EM; Mavrakis HE; Kambouraki DC; Arfanakis DA; Vardas PE
    Chest; 2005 Oct; 128(4):2604-10. PubMed ID: 16236931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining potential to benefit from implantable cardioverter defibrillator therapy: the role of biomarkers.
    Scott PA; Townsend PA; Ng LL; Zeb M; Harris S; Roderick PJ; Curzen NP; Morgan JM
    Europace; 2011 Oct; 13(10):1419-27. PubMed ID: 21784745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain natriuretic peptide and the risk of ventricular tachyarrhythmias in mildly symptomatic heart failure patients enrolled in MADIT-CRT.
    Medina A; Moss AJ; McNitt S; Zareba W; Wang PJ; Goldenberg I
    Heart Rhythm; 2016 Apr; 13(4):852-9. PubMed ID: 26724489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal pro-B-type natriuretic peptide for prediction of ventricular arrhythmias: Data from the SMASH study.
    Sourour N; Riveland E; Naesgaard P; Kjekshus H; Larsen AI; Omland T; Røsjø H; Myhre PL
    Clin Cardiol; 2023 Aug; 46(8):989-996. PubMed ID: 37400982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.
    Kistorp C; Raymond I; Pedersen F; Gustafsson F; Faber J; Hildebrandt P
    JAMA; 2005 Apr; 293(13):1609-16. PubMed ID: 15811980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining the use of amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the prognosis of hospitalized heart failure patients.
    Wang Y; Zhang R; Huang Y; Zhai M; Zhou Q; An T; Huang Y; Zhao X; Tian P; Zhang Y; Zhang J
    Clin Chim Acta; 2019 Apr; 491():8-14. PubMed ID: 30594544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction.
    Costello-Boerrigter LC; Boerrigter G; Redfield MM; Rodeheffer RJ; Urban LH; Mahoney DW; Jacobsen SJ; Heublein DM; Burnett JC
    J Am Coll Cardiol; 2006 Jan; 47(2):345-53. PubMed ID: 16412859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased N-terminal-pro-B-type natriuretic peptide levels in patients with appropriate implantable defibrillator therapies.
    Arnaldo FJ; Anatoliotakis N; Palacio C; Nabert DR; Hsu SS
    Heart Lung; 2009; 38(1):10-6. PubMed ID: 19150526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NT-proBNP Predicts Cardiovascular Death in the General Population Independent of Left Ventricular Mass and Function: Insights from a Large Population-Based Study with Long-Term Follow-Up.
    Dietl A; Stark K; Zimmermann ME; Meisinger C; Schunkert H; Birner C; Maier LS; Peters A; Heid IM; Luchner A
    PLoS One; 2016; 11(10):e0164060. PubMed ID: 27711172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.
    Kragelund C; Grønning B; Køber L; Hildebrandt P; Steffensen R
    N Engl J Med; 2005 Feb; 352(7):666-75. PubMed ID: 15716560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BNP and NT-proBNP, predictors of 1-year mortality in nursing home residents.
    Barents M; Hillege HH; van der Horst IC; de Boer RA; Koster J; Muskiet FA; de Jongste MJ
    J Am Med Dir Assoc; 2008 Oct; 9(8):580-5. PubMed ID: 19083292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LGE and NT-proBNP identify low risk of death or arrhythmic events in patients with primary prevention ICDs.
    Mordi I; Jhund PS; Gardner RS; Payne J; Carrick D; Berry C; Tzemos N
    JACC Cardiovasc Imaging; 2014 Jun; 7(6):561-9. PubMed ID: 24813968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB
    J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-terminal pro-B-type natriuretic peptide-ratio predicts mortality after transcatheter aortic valve replacement.
    Stähli BE; Gebhard C; Saleh L; Falk V; Landmesser U; Nietlispach F; Maisano F; Lüscher TF; Maier W; Binder RK
    Catheter Cardiovasc Interv; 2015 Jun; 85(7):1240-7. PubMed ID: 25511571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early discharge after primary percutaneous coronary intervention: the added value of N-terminal pro-brain natriuretic peptide to the Zwolle Risk Score.
    Schellings DA; Adiyaman A; Giannitsis E; Hamm C; Suryapranata H; Ten Berg JM; Hoorntje JC; Van't Hof AW
    J Am Heart Assoc; 2014 Nov; 3(6):e001089. PubMed ID: 25389283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.